

Supplementary Table 3: GWAS summary statistics used to test genetic correlations with treatment-resistant depression (TRD) and non-TRD using linkage disequilibrium score regression (LDSC) in UKB. ADHD=attention deficit hyperactivity disorder; ASD=autism spectrum disorders;

Trait	Type of phenotype	N cases	N controls	Ethnicity	Reference (PubMed ID)
Psychiatric disorders					
Major depressive disorder*^	Binary	45,591	97,674	European	29700475
Depressive symptoms	Continuous	105,739		European	27089181
	Binary	16,471	58,656		
Bipolar disorder^	Binary	20,352	31,358	European	31043756
Schizophrenia	Binary	36,989	113,075	European	25056061
ADHD	Continuous	17,666		European	27663945
ASD	Binary	18,381	27,969	European	30804558
Anorexia nervosa^	Binary	16,992	55,525	European	31308545
PGC cross-disorder study	Binary	33,332	27,888	European	23453885
Personality and related traits					
Neuroticism	Continuous	170,911		European	27089181
Openness to experience	Continuous	17,375		European	21173776
Conscientiousness	Continuous	17,375		European	21173776
Subjective wellbeing	Continuous	298,420		European	27089181
Sleep-related traits					
Insomnia	Binary	32,155	26,973	European	27992416
Sleep duration	Continuous	128,266		European	27494321
Chronotype (morningness)	Continuous	128,266		European	27494321
Cognitive and related traits					
Childhood IQ	Continuous	17,989		European	23358156
Intelligence	Continuous	78,308		European	28530673
Years of schooling	Continuous	293,723		European	27225129
College completion	Continuous	126,559		European	23722424
Cardio-metabolic and related traits					
LDL cholesterol	Continuous	95,454		European	20686565
HDL cholesterol	Continuous	99,900		European	20686565
Triglycerides	Continuous	96,598		European	20686565
Type 2 diabetes	Binary	34,840	114,981	European	22885922
Coronary artery disease	Binary	60,801	123,504	European and south Asian	26343387
Ever smoked	Binary	41,951	32,102	European	20418890
Obesity class 1	Binary	55,229	104,894	European	23563607
Obesity class 2	Binary	15,334	97,858	European	23563607
Obesity class 3	Binary	3,986	67,010	European	23563607
BMI	Continuous	249,796		European	20935630
Waist-to-hip ratio	Continuous	224,459		European	25673412

* Subjects from UK Biobank and 23AndMe were excluded

^ The genetic correlations with the TRD phenotypes were not estimated using LD Hub for these traits but using the software on a local machine because of the availability of significantly smaller datasets on LD Hub compared to the most recent studies

Definitions of obesity:

Obesity class 1: BMI ≥ 30 kg/m²

Obesity class 2: BMI ≥ 35 kg/m²

Obesity class 3: BMI ≥ 40 kg/m²

Supplementary Table 4: GWAS summary statistics used to create the polygenic risk scores (PRSs) in UKB and EXCEED (in EXCEED only PRS for major depressive disorder, schizophrenia and bipolar disorder were tested for association with depression defined using primary care data).

Trait	Type of phenotype	N cases	N controls	Ethnicity	Reference (PubMed ID)
Psychiatric disorders					
Major depressive disorder*	Binary	45,591	97,674	European	29700475
Schizophrenia	Binary	36,989	113,075	European	25056061
Bipolar disorder	Binary	20,352	31,358	European	31043756
Attention-deficit hyperactivity disorder	Binary	20,183	35,191	European	30478444
Personality and related traits					
Neuroticism	Continuous	63,030		European	25993607
Subjective wellbeing**	Continuous	298,420		European	27089181
Cognitive traits					
Intelligence	Continuous	269,867		European	29942086
Childhood IQ	Continuous	12,441		European	23358156

* Subjects included in UK Biobank and 23AndMe were excluded from the analyses

** 4,876 participants from UK Biobank were included in both this previous study and the present one

Supplementary Table 5: (A) results of the association analyses between the PRS of major depressive disorder (MDD), bipolar disorder and schizophrenia with depression diagnosis in UK Biobank primary care data (at least two or more diagnostic codes or at least one diagnostic code). For each measure of MDD, the number of cases and controls included in the analysis is shown in parenthesis. Results referred to the best p threshold (P_T) are shown, but they were consistent across different p thresholds tested. Nagelkerke R2 was reported on the liability scale considering a prevalence of 10.8% (Lim et al., 2018) for the MDD definition based on primary care records (\geq two GP codes depression), while for the other MDD phenotypes we considered the relative prevalence compared to \geq two GP codes depression (e.g. \geq one GP code depression was 1.59 times more common than \geq two GP codes depression: $10.8\% \times 1.59 = 17.17\%$). After Bonferroni correction, $\alpha=2.16e-04$. **(B)** Results of the association analyses between the PRS of major depressive disorder (MDD), bipolar disorder and schizophrenia with depression diagnosis in the EXCEED sample. After Bonferroni correction, $\alpha=1.52e-03$.

A

Base data	Target trait	Best P_T	E (SE)	P	OR (95% CI)	Nagelkerke R2
Major depressive disorder	\geq two GP codes depression (17,807 vs. 130,356)	0.3	0.15 (0.008)	2.73e-71	1.16 (1.14-1.17)	0.0055
Bipolar disorder		0.5	0.07 (0.008)	2.63e-17	1.07 (1.06-1.09)	0.0012
Schizophrenia		1	0.09 (0.008)	4.30e-25	1.09 (1.07-1.11)	0.0018
Major depressive disorder	\geq one GP code depression (30,822 vs. 130,356)	0.5	0.14 (0.006)	3.70e-100	1.15 (1.13-1.16)	0.0056
Bipolar disorder		0.05	0.06 (0.006)	3.92e-21	1.06 (1.05-1.08)	0.0012
Schizophrenia		0.3	0.08 (0.007)	4.98e-34	1.08 (1.07-1.10)	0.0018
Major depressive disorder	MHQ-depression (28,824 vs 83,203)	0.4	0.13 (0.007)	2.65e-84	1.14 (1.13-1.16)	0.0060
Bipolar disorder		0.3	0.08 (0.007)	1.60e-31	1.09 (1.07-1.10)	0.0022
Schizophrenia		0.1	0.11 (0.007)	5.70e-50	1.11 (1.10-1.13)	0.0035
Major depressive disorder	ICD depression (13,172 vs 293,833)	0.2	0.15 (0.009)	2.61e-63	1.16 (1.14-1.18)	0.0044
Bipolar disorder		0.3	0.08 (0.009)	2.89e-19	1.09 (1.07-1.11)	0.0013
Schizophrenia		1	0.08 (0.009)	4.54e-17	1.08 (1.06-1.10)	0.0011
Major depressive disorder	Smith depression (24,627 vs 64,476)	0.5	0.14 (0.008)	1.04e-74	1.15 (1.13-1.17)	0.0065
Bipolar disorder		0.1	0.08 (0.008)	2.06e-27	1.09 (1.07-1.10)	0.0023
Schizophrenia		0.4	0.10 (0.008)	4.34e-41	1.11 (1.09-1.13)	0.0035
Major depressive disorder	Self-rep. depression (25,932 vs 85,361)	0.5	0.16 (0.007)	6.02e-106	1.17 (1.15-1.19)	0.0080
Bipolar disorder		0.3	0.08 (0.007)	4.79e-28	1.08 (1.07-1.10)	0.0020
Schizophrenia		0.4	0.09 (0.007)	7.09e-36	1.10	0.0026

					(1.08-1.11)	
Major depressive disorder	Seen GP or psychiatrist (135,947 vs 240,385)	0.3	0.14 (0.003)	<1e-200	1.14 (1.14-1.15)	0.0065
Bipolar disorder		0.4	0.08 (0.004)	2.32e-123	1.09 (1.08-1.09)	0.0024
Schizophrenia		0.4	0.10 (0.004)	1.38e-176	1.11 (1.10-1.11)	0.0034

B

Base data	Target trait	Best P _T	E (SE)	P	OR (95% CI)	Nagelkerke R ²
Major depressive disorder	≥ 2 GP codes for depression (557 vs 2,181)	0.2	0.23 (0.05)	6.05e-06	1.26 (1.14-1.39)	0.0124
Bipolar disorder		0.05	0.14 (0.05)	0.0060	1.15 (1.04-1.26)	0.0045
Schizophrenia		0.05	0.11 (0.05)	0.0276	1.12 (1.01- 1.23)	0.0029

Supplementary Table 6: overlap between MDD defined according to primary care data (at least two diagnostic codes for depression) with other depression measures in UK Biobank. The overlap between participants having no diagnostic code for depression and participants having at least one diagnostic code for depression is reported for comparison. For each pair of depression phenotypes (non-primary care vs. primary care), the number of subjects having depression according to both / total number of subjects having both depression measures is reported and the corresponding percentage in parenthesis. A Fisher's exact test was used to compare the difference in overlap between those having at least two diagnostic codes for depression, one diagnostic code for depression and no diagnostic code for depression. * p values < Bonferroni corrected p value of 5e-3. GP=general practitioner.

Depression measure	Overlap with >= two depression diagnostic codes in primary care	Overlap with one depression diagnostic code in primary care	Overlap with no depression diagnostic code in primary care	Overlap in those with at least two vs. at least one depression diagnostic code	Overlap in those with at least two vs. no depression diagnostic code
ICD depression	3380/17024 (19.85%)	4863/31361 (15.51%)	2529/151412 (1.67%)	OR=1.28 (1.22-1.34), p=5.69e-24*	OR=11.89 (11.25-12.55), p<2.2e-16*
Smith depression	3774/5013 (75.28%)	6312/9159 (68.92%)	9286/48234 (19.25%)	OR=1.09 (1.04-1.15), p=1.14 e-03*	OR=3.91 (3.73-4.10), p<2.2e-16*
Self-reported depression	4047/4616 (87.67%)	6832/8412 (81.22%)	7594/53485 (14.20%)	OR=1.08 (1.02-1.14), p=4.75e-03*	OR=6.17 (5.88-6.48), p<2.2e-16*
MHQ-defined depression	3217/4444 (72.39%)	5462/8180 (66.77%)	10834/54317 (19.95%)	OR=1.08 (1.02-1.15), p=5.52e-03	OR=3.63 (3.45-3.82), p<2.2e-16*
Seen GP or psychiatrist for depression	17301/19637 (88.10%)	29714/36128 (82.25%)	49892/185601 (26.88%)	OR=1.07 (1.04-1.10), p=1.35e-07*	OR=3.28 (3.20-3.35), p<2.2e-16*

Supplementary Table 7: Clinical and socio-demographic variables tested for association with treatment-resistant depression (TRD) compared to non-TRD in UKB; after Bonferroni correction $\alpha=1.39e-03$. Logistic regression (beta (SE) or OR (95% CI) are reported for continuous and binary predictors, respectively) or Kruskal-Wallis test were used.

Variable	TRD n=2,430	Non-TRD n=15,951	Effect size or statistics	p-value	N missing
Number in household (>1/total)	577/2404 (24.00%)	3726/15805 (23.57%)	OR = 0.98 (0.88 – 1.08)	0.65	172
Leisure - social activities (yes/total)	1511/2421 (62.41%)	10377/15860 (65.43%)	OR = 0.89 (0.81 – 0.97)	0.007	100
Able to confide (where 0 is never and 5 is daily)	3.14 (1.95)	3.34 (1.92)	Kruskal-Wallis $\chi^2 = 23.52$	1.25e-06	570
Frequency of visits from family/friends (0-7)	2.69 (1.23)	2.69 (1.17)	Kruskal-Wallis $\chi^2 = 13.87$	0.031	152
Days/week of moderate physical activity*	3.33 (2.45)	3.53 (2.40)	beta = -0.09 (0.02)	1.39e-04	1276
Longstanding illness or disability yes/total **	1534/2333 (65.75%)	6906/15409 (44.82%)	OR = 2.26 (2.06 – 2.49)	5.45e-64	639
Education (% per category)***	College: 22.22% A-levels: 11.79% 0-levels-GCSEs: 22.72% CSEs: 7.10% NVQ-HND-HNC: 6.15% Other professional title: 5.23% None of the above: 24.79%	College: 27.84% A-levels: 11.28% 0-levels-GCSEs: 22.42% CSEs: 6.62% NVQ-HND-HNC: 7.09% Other professional title: 5.34% None of the above: 19.47%	OR = 0.64 (0.56 – 0.73) OR = 0.84 (0.72 – 0.98) OR = 0.80 (0.70 – 0.91) OR = 0.86 (0.71 – 1.05) OR = 0.70 (0.58 – 0.85) OR = 0.77 (0.63 – 0.95) Reference level	1.61e-11 0.029 0.00076 0.13 0.00033 0.014	239
Average household income £ (% per category)	<18K: 41.98% 18K-30.9K: 26.28% 31K-51.9K: 20.67% 52K-100K: 10.14% >100K: 0.94%	<18K: 31.01% 18K-30.9K: 26.90% 31K-51.9K: 24.17% 52K-100K: 15.23% >100K: 2.69%	Reference level OR = 0.72 (0.64 – 0.81) OR = 0.63 (0.56 – 0.72) OR = 0.49 (0.42 – 0.58) OR = 0.26 (0.16 – 0.41)	4.62e-08 7.08e-13 5.81e-18 1.13e-08	2793
Personality traits at baseline (available in the whole UKB cohort)					
“Are you often troubled by feelings of guilt?” (yes/total)	1366/2350 (58%)	7248/15419 (47%)	OR = 1.56 (1.43 – 1.71)	1.63e-23	612
“Do you often feel lonely?” (yes/total)	1190/2369 (50.23%)	5819/15543 (37.43%)	OR = 1.69 (1.55 – 1.84)	3.98e-32	469

"Are your feelings easily hurt?" (yes/total)	1898/2365 (80.25%)	11383/15521 (73.34%)	OR = 1.48 (1.33 – 1.64)	1.01e-12	495
"Do you ever feel 'just miserable' for no reason?" (yes/total)	1984/2393 (82.91%)	11227/15650 (71.74%)	OR = 1.91 (1.71 – 2.14)	8.72e-30	338
"Are you an irritable person?" (yes/total)	1197/2297 (51.11%)	6278/15060 (41.69%)	OR = 1.52 (1.39 – 1.66)	8.44e-21	1024
"Does your mood often go up and down?" (yes/total)	2057/2397 (85.82%)	11571/15635 (74.01%)	OR = 2.12 (1.88 – 2.40)	9.97e-35	349
"Would you call yourself a nervous person?" (yes/total)	1201/2339 (51.35%)	5930/15385 (38.54%)	OR = 1.68 (1.54 – 1.84)	1.64e-31	657
Neuroticism score	7.97 (3.15)	6.35 (3.30)	beta = 0.46 (0.03)	3.0e-66	4089
"Would you describe yourself as someone who takes risks?" (yes/total)	585/2327 (25.14%)	3982/15245 (26.12%)	OR = 0.95 (0.86 – 1.05)	0.32	809

* adjusted for age and sex; no longer significant if adjusted also for long-term disability or illness (p=3.29e-03)

** adjusted for age, sex, BMI and ever smoked

*** adjusted for age and sex

Supplementary Table 8: psychiatric comorbidities in patients with treatment-resistant depression (TRD) vs. non-TRD according to primary care records in UKB.

Comorbidities	TRD (n=2,430)	Non-TRD (n=15,951)	Effect size	P value
Anxiety disorders	997 (41.03%)	4290 (26.89%)	OR=1.89 (1.73-2.07)	1.25e-45
Depression with anxiety	904 (37.20%)	4950 (31.03%)	OR=1.32 (1.20-1.44)	1.30e-09
Obsessive-compulsive disorder	60 (2.47%)	132 (0.083%)	OR=3.03 (2.23-4.13)	1.69e-12
Somatoform disorders	195 (8.02%)	860 (5.39%)	OR=1.53 (1.30-1.80)	2.43e-07
Stress-related disorders	196 (8.07%)	1014 (6.36%)	OR=1.29 (1.10-1.52)	0.0016
Eating disorders	45 (1.85%)	127 (0.080%)	OR=2.35 (1.67-3.31)	1.02e-06
Sleep disorders	83 (3.42%)	304 (1.91%)	OR=1.82 (1.42-2.33)	1.93e-06
Personality disorders	55 (2.26%)	147 (0.092%)	OR=2.49 (1.82-3.40)	1.09e-08
Self-harm/suicidal behaviours	132 (5.43%)	438 (2.28%)	OR=2.03 (1.67-2.48)	2.99e-12

Supplementary Table 9: frequency of psychotropic drug combinations (A), type of antidepressant drug combinations (B) and combinations based on drug classes (C) in UKB. Antidepressant augmentation with any antipsychotic or a mood stabilizer among lithium, valproate, lamotrigine and pregabalin were considered in patients with TRD and non-TRD. Only combinations prescribed for longer than 30 days were considered. When considering specific drug or class combinations, only those prescribed to > 15 subjects were considered. Fisher's exact test was used for comparisons because of the small size of some of the groups. Bonferroni corrected p values was 2.38e-03 and 1.43e-03 for the comparisons in B and C, respectively.

* significant difference between TRD and non-TRD.

A

Drug combination	TRD (n=2430)	Non-TRD (n=15951)	Statistics
Antidepressant combination	1128 (46.42%)	1307 (8.19%)	OR=5.66 (5.17-6.21), p=4.03e-289*
Augmentation with antipsychotic	354 (14.57%)	576 (3.61%)	OR=4.03 (3.50-4.65), p=2.95e-75*
Augmentation with mood stabilizer	326 (13.42%)	406 (2.55%)	OR=5.27 (4.51-6.15), p=4.33e-90*

B

Drug combination	TRD	Non-TRD	Statistics
amitriptyline-citalopram	198 (17.55%)	266 (20.35%)	OR=0.86 (0.70-1.06), p=0.15
amitriptyline-fluoxetine	144 (12.77%)	245 (18.75%)	OR=0.68 (0.54-0.85), p=6.56e-04*
amitriptyline-mirtazapine	73 (6.47%)	49 (3.75%)	OR=1.73 (1.17-2.55), p=3.87e-03
amitriptyline-paroxetine	32 (2.84%)	39 (2.98%)	OR=0.95 (0.57-1.57), p=0.90
amitriptyline-duloxetine	16 (1.42%)	12 (0.92%)	OR=1.54 (0.68-3.59), p=0.26
amitriptyline-sertraline	112 (9.93%)	121 (9.26%)	OR=1.07 (0.81-1.42), p=0.63
amitriptyline-venlafaxine	58 (5.14%)	8 (3.67%)	OR=8.39 (3.97-20.44), p=4.69e-12*
citalopram-dosulepin	20 (1.77%)	7 (0.54%)	OR=3.31 (1.34-9.30), p=5.62e-03
citalopram-fluoxetine	60 (5.32%)	30 (2.30%)	OR=2.32 (1.46-3.75), p=1.51e-04*
citalopram-mirtazapine	50 (4.43%)	58 (4.44%)	OR=1 (0.66-1.50), p=1
citalopram-sertraline	41 (3.63%)	32 (2.45%)	OR=1.48 (0.91-2.45), p=0.12
citalopram-venlafaxine	16 (1.42%)	6 (0.05%)	OR=3.09 (1.14-9.67), p=0.017
fluoxetine-mirtazapine	33 (2.93%)	25 (1.91%)	OR=1.53 (0.88-2.70), p=0.14
fluoxetine-sertraline	49 (4.34%)	11 (0.084%)	OR=5.16 (2.63-11.06), p=4.83e-08*

mirtazapine-sertraline	46 (4.08%)	38 (2.91%)	OR=1.40 (0.89-2.23), p=0.15
mirtazapine-venlafaxine	82 (7.27%)	65 (4.97%)	OR=1.46 (1.03-2.08), p=0.027
trazodone-citalopram	13 (1.15%)	18 (1.38%)	OR=0.84 (0.38-1.82), p=0.72
trazodone-fluoxetine	14 (1.24%)	19 (1.45%)	OR=0.85 (0.39-1.81), p=0.73
trazodone-venlafaxine	16 (1.42%)	12 (0.092%)	OR=1.54 (0.68-3.59), p=0.26
venlafaxine-citalopram	16 (1.42%)	12 (0.092%)	OR=1.54 (0.68-3.59), p=0.26
venlafaxine-sertraline	16 (1.42%)	3 (0.022%)	OR=6.17 (1.76-33.17), p=9.35e-04*

C

Drug combination	TRD	Non-TRD	Statistics
SNRI-NaSSA	97 (5.93%)	64 (4.45%)	OR=1.33 (0.95-1.87), p=0.09
SNRI-SARI	29 (1.78%)	23 (1.60%)	OR=1.11 (0.62-2.01), p=0.78
SNRI-SNRI	16 (0.98%)	2 (0.14%)	OR=7.09 (1.65-63.08), p=0.0031
SSRI-NaSSA	165 (10.08%)	128 (8.91%)	OR=1.13 (0.88-1.45), p=0.33
SSRI-phenothiazine	19 (1.16%)	8 (0.06%)	OR=2.08 (0.87-5.52), p=0.08
SSRI-SARI	70 (4.28%)	68 (4.73%)	OR=0.90 (0.63-1.29), p=0.60
SSRI-SNRI	126 (7.70%)	59 (4.11%)	OR=1.87 (1.35-2.62), p=7.33e-05*
SSRI-SSRI	195 (11.91%)	105 (7.31%)	OR=1.63 (1.27-2.11), p=9.75e-05*
TCA-NaSSA	94 (5.74%)	63 (4.38%)	OR=1.31 (0.93-1.85), p=0.12
TCA-SARI	41 (2.50%)	26 (1.81%)	OR=1.38 (0.82-2.37), p=0.22
TCA-SNRI	119 (7.27%)	99 (6.89%)	OR=1.06 (0.79-1.41), p=0.73
TCA-SSRI	594 (36.29%)	760 (52.89%)	OR=0.69 (0.60-0.78), p=9.17e-09*
TCA-TCA	72 (4.40%)	32 (2.23%)	OR=1.97 (1.28-3.12), p=0.0013*
NaSSA-atypical AP	63 (10.29%)	75 (9.99%)	OR=1.03 (0.71-1.49), p=0.93
NaSSA-typical AP	26 (4.25%)	29 (3.86%)	OR=1.10 (0.62-1.96), p=0.78
SARI-atypical AP	20 (3.27%)	15 (2.0%)	OR=1.64 (0.79-3.47), p=0.17
SARI-typical AP	26 (4.25%)	17 (2.26%)	OR=1.88 (0.97-3.72), p=0.06
SNRI-atypical AP	66 (10.78%)	84 (11.19%)	OR=0.96 (0.68-1.37), p=0.96
SNRI-typical AP	49 (8.01%)	46 (6.13%)	OR=1.31 (0.84-2.03), p=0.24
SSRI-atypical AP	97 (15.85%)	124 (16.51%)	OR=0.96 (0.71-1.29), p=0.83
SSRI-typical AP	131 (21.41%)	215 (28.63%)	OR=0.75 (0.58-0.96), p=0.021
TCA atypical AP	40 (6.54%)	35 (4.60%)	OR=1.40 (0.86-2.30), p=0.16
TCA typical AP	94 (15.36%)	111 (14.78%)	OR=0.82 (0.76-1.41), p=0.82
NaSSA-lithium	31 (6.11%)	18 (3.11%)	OR=1.97 (1.05-3.78), p=0.028
NaSSA-pregabalin	46 (9.07%)	28 (4.84%)	OR=1.88 (1.13-3.16), p=0.011

SARI-lithium	16 (3.16%)	8 (1.38%)	OR=2.28 (0.91-6.21), p=0.06
SNRI-lithium	46 (9.07%)	36 (6.22%)	OR=1.46 (0.91-2.36), p=0.11
SNRI-pregabalin	47 (9.27%)	43 (7.43%)	OR=1.25 (0.79-1.97), p=0.32
SSRI-lamotrigine	23 (4.54%)	15 (2.59%)	OR=1.75 (0.86-3.65), p=0.10
SSRI-lithium	61 (12.03%)	27 (4.66%)	OR=2.58 (1.59-4.29), p= 5.31e-05*
SSRI-pregabalin	134 (26.43%)	148 (25.56%)	OR=1.03 (0.79-1.36), p=0.84
SSRI-valproate	27 (5.33%)	25 (4.32%)	OR=1.23 (0.68-2.25), p=0.48
TCA-lithium	43 (8.48%)	32 (5.53%)	OR=1.53 (0.93-2.55), p=0.09
TCA-pregabalin	84 (16.57%)	119 (2.06%)	OR=0.80 (0.59-1.10), p=0.17
TCA-valproate	21 (4.12%)	8 (1.38%)	OR=2.99 (1.26-7.89), p=0.0076

Supplementary Table 12: results of the association analyses between the PRS of interest and the risk of treatment-resistant depression (TRD) vs. non-TRD in UKB. Nagelkerke R2 is reported on the observed scale since the comparison is referred to cases only. *significant results after Bonferroni correction ($p=5.81e-04$). P_T = p threshold.

Base data	Best P_T	E (SE)	P	OR (95% CI)	Nagelkerke R2
Major depressive disorder	0.001	0.05 (0.02)	0.028	1.05 (1.01-1.10)	5.36e-04
Attention-deficit hyperactivity disorder	0.2	0.08 (0.02)	4.38e-04*	1.09 (1.04-1.14)	1.38e-03
Schizophrenia	0.1	0.04 (0.02)	0.14	1.04 (0.99-1.09)	2.48e-04
Bipolar disorder	0.01	0.04 (0.02)	0.07	1.04 (0.99-1.09)	3.74e-04
Neuroticism	0.01	0.06 (0.02)	7.42e-03	1.06 (1.02-1.11)	7.98e-04
Subjective well-being	0.2	-0.08 (0.02)	1.32e-03	0.93 (0.89-0.97)	1.15e-03
Intelligence	0.1	-0.09 (0.02)	3.08e-04*	0.92 (0.87-0.96)	1.45e-03
Childhood IQ	0.05	-0.02 (0.02)	0.50	0.98 (0.94-1.03)	5.02e-05